ESPE2018 Poster Presentations Pituitary, Neuroendocrinology and Puberty P2 (37 abstracts)
aDepartement of Pediatrics, Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea; bDepartement of Pediatrics, Kangdong Sacred Heart Hospital, Hallym University, College of Medicine, Seoul, Republic of Korea; cDepartement of Pediatrics, Wonkwang University Sanbon Hospital, Gunpo, Republic of Korea
Background/aim: Anti Müllerian hormone (AMH) and Inhibin B (INHB) are considered as possible biomarker of central precocious puberty(CPP). This study investigated serum AMH and INHB level in central precocious puberty andanalyzed clinical factors associated with these two hormone levels.
Methods: In total, 48 girls with CPP and 35 age matched prepubertal girls were enrolled in the study. The subjects were divided into two groups as CPP and control. AMH and INHB levels were determined in the two groups. In CPP group, AMH and INHB level were evaluated in pretreatment, six - months and 12 months after GnRH agonist (GnRHa) treatment.
Results: The mean INHB levels of the CPP group were significantly higher than control (54.82±48.65 and 16.17±7.01 pg/l, respectively, P<0.001). AMH levels were not different between two groups. After GnRHa treatment, AMH and INHB levels were decreased significantly. Age was negatively correlated with AMH and positively correlated with INHB.
Conclusions: Inhibin B level is possible marker to differentiated CPP to control and reversed with GnRHatreatment in CPP. It remains unclear whether a decrease in AMH is due to the effect of GnRHa or a natural decrease in age.